Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference12 articles.
1. Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent;Verweij;Oncology Res,1994
2. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models;Hendriks;Eur J Cancer,1993
3. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents;Workman;Int J Radiat Oncol Biol Phys,1992
4. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9;Schellens;J Natl Cancer Inst,1994
5. Phase I study of the bioreductive indoloquinone EO9;Lund;Ann Oncol,1994
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy;Frontiers in Oncology;2021-07-29
2. Synthetic DNA‐Targeted Chemotherapeutic Agents And Related Tumor‐Activated Prodrugs;Burger's Medicinal Chemistry and Drug Discovery;2021-04-26
3. Apaziquone for Nonmuscle Invasive Bladder Cancer;Urologic Clinics of North America;2020-02
4. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs;Cancer Chemotherapy and Pharmacology;2016-01-25
5. Pharmacokinetic Modeling;Cancer Drug Discovery and Development;2013-11-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3